AU Patent

AU2021254650B2 — Intranasal epinephrine formulations and methods for the treatment of disease

Assigned to Ars Pharmaceuticals Operations Inc · Expires 2024-02-22 · 2y expired

What this patent protects

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

USPTO Abstract

Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021254650B2
Jurisdiction
AU
Classification
—
Expires
2024-02-22
Drug substance claim
No
Drug product claim
No
Assignee
Ars Pharmaceuticals Operations Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.